The archive in the attic: what this domain's first tenant knew about dengue twenty years early

Before this domain was a newsroom, it was the press page of a working biotech. From 2002 to 2016, hibiotech.com belonged to Hawaii Biotech, an Aiea-based vaccine developer that spent fifteen years trying to solve the exact problem the field is still solving in 2026: how to make a safe dengue vaccine. Its press archive, 59 releases spanning grant awards, partnerships and publications, reads like a rough draft of today's flavivirus headlines. It is also a museum of how biotech time works.

What the tenant knew

The archive's spine is dengue. There are NIH grant notices, coverage of early clinical work, and citations to a 2001 immunology paper whose authors were already worried about the problem that would later sink Dengvaxia: immune responses to dengue are double-edged, and a vaccine that produces the wrong kind of protection can make the next infection worse. The company's scientists wrote about antibody-dependent enhancement risk before most of the industry had heard the phrase. A TIGR newsletter from the era asked whether a billion-dollar biotech could really grow in Hawaii; BioWorld covered the program's progress in 2003; a business combination with Avantogen promised the scale-up.

And then the archive does what archives do: it reveals the gap between knowing and doing. The dengue candidate never became a product. The company diversified into West Nile, into biodefense work including a 2014 anthrax grant, into chikungunya with a 2016 award, the way small biotechs follow funding wherever it leads. The last release in the file is from early 2017. Then the domain went quiet, and eventually, the company let it lapse.

Twenty years early

Here is the uncomfortable part. Nearly every scientific bet in those releases was correct: dengue would become a global emergency, West Nile would become endemic in the United States, chikungunya would follow the mosquitoes north, vaccine platforms would matter for pandemic response. The archive is a catalogue of right answers filed by a company that could not afford to wait for them to be recognized.

That is the quiet lesson this publication takes from its own attic. In biotech, being right is the entry fee, not the prize. The distance between a correct hypothesis in 2003 and a national immunization program in 2026 is filled with financing risk, trial design, regulatory timing, and the raw luck of being solvent when your science becomes urgent. The field's current consensus targets were once somebody's unfundable idea.

Why we keep the archive public

We have republished the full press archive on this site, not as nostalgia but as primary evidence. It documents two decades of flavivirus vaccinology from the Pacific edge of the industry, and it is a standing reminder of the editorial standard we hold ourselves to: the science getting funded has a history, and the history is often more honest than the pitch deck. The attic had it right twenty years early. Our job is to tell you who has it right now, and who can afford to wait.

The brief: hibiotech.com's first tenant spent 2002 to 2016 pursuing dengue, West Nile and chikungunya vaccines, called the field's hardest problems early, and ran out of runway before the answers became urgent. We keep the archive as evidence that in biotech, timing is the science nobody can fund.